BETHESDA, Md., Sept. 30, 2014
/PRNewswire/ -- Chindex International, Inc. ("Chindex" or the
"Company") (Nasdaq: CHDX) today announced the completion of its
acquisition by Healthy Harmony Holdings, L.P. ("Healthy Harmony")
for $24.00 per share in cash.
Healthy Harmony is an affiliate of TPG, Shanghai Fosun
Pharmaceutical (Group) Co., Ltd. ("Fosun") and Ms. Roberta Lipson, the CEO of the Company.
The previously announced merger agreement was adopted by
Chindex's stockholders at a special meeting of stockholders held on
September 16, 2014. As a result
of the merger, Chindex is now a privately held company, owned by
Healthy Harmony, and Chindex's common stock will be delisted from
NASDAQ.
Morgan Stanley & Co. LLC served as financial advisor and
Hughes Hubbard & Reed LLP served as lead legal advisor to the
Transaction Committee of the Board of Directors of Chindex in
connection with the merger. Goldman, Sachs & Co. served
as financial advisor, Cleary Gottlieb
Steen & Hamilton LLP served as lead legal advisor, and
Fangda Partners served as PRC counsel to TPG. Troutman Sanders LLP
served as Fosun's legal advisor. Skadden, Arps, Slate, Meagher
& Flom LLP served as lead legal advisor to Ms. Lipson.
About Chindex
Chindex is an American health care company providing health care
services in China through the
operations of United Family Healthcare, a network of private
primary care hospitals and affiliated ambulatory clinics. United
Family Healthcare currently operates in Beijing, Shanghai, Tianjin and Guangzhou. The Company also provides medical
capital equipment and products through Chindex Medical Ltd., a
joint venture company with manufacturing and distribution
businesses serving both domestic China and export markets. With more than
thirty years of experience, the Company's strategy is to continue
its growth as a leading integrated health care provider in the
Greater China region. Further
Company information may be found at the Company's website at
http://www.chindex.com.
About TPG
TPG is a leading global private investment firm founded in 1992
with $66 billion of assets under
management and offices in San
Francisco, Fort Worth,
Austin, Dallas, Houston, New
York, Beijing, Hong Kong, London, Luxembourg, Melbourne, Moscow, Mumbai, Sao
Paulo, Shanghai,
Singapore and Tokyo. TPG has extensive experience with
global public and private investments executed through leveraged
buyouts, recapitalizations, spinouts, growth investments, joint
ventures and restructurings. The firm's investments span a variety
of industries including financial services, travel and
entertainment, technology, energy, industrials, retail, consumer,
real estate, media and communications, and healthcare. Chindex is
an extension of TPG's history of investing in and adding value to
leading healthcare services platforms in Asia and globally, including our investments
in Parkway, Healthscope and Surgical Care Affiliates. TPG's past
and present investments in China
include China Grand Auto , China International Capital Corporation,
Daphne, HCP Holdings, Lenovo, Li
Ning, Phoenix Satellite Television, Shenzhen Development
Bank (currently Ping An Bank) and
UniTrust. For more information, please visit www.tpg.com.
About Fosun Industrial
Fosun Industrial, a wholly-owned subsidiary of Shanghai Fosun
Pharmaceutical (Group) Co., Ltd, was established in 2004 and
registered in Hong Kong. Mr. CHEN
Qiyu is the Chairman of the company. Fosun Industrial is
principally engaged in foreign investment, the sales and
consultation service of Chinese and Western medicine, diagnostic
reagent and pharmaceutical equipment and related import and export
business.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma")
holds 100% equity interest in Fosun Industrial. Fosun Pharma (stock
code: 600196-SH ,02196-HK) is a leading healthcare company in
China established in 1994 and
listed on the Shanghai Stock Exchange and main board of The Stock
Exchange of Hong Kong in
August 1998 and October 2012, respectively. It is engaged in
various businesses including pharmaceutical manufacturing,
distribution and retail, healthcare services and diagnostic
products and medical devices. Please visit www.fosunpharma.com for
further information.
Safe Harbor Statement
Statements made in this press release relating to plans,
strategies, objectives, economic performance and trends and other
statements that are not descriptions of historical facts may be
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended (the "Securities Act"), and
Section 21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"). Forward-looking information is inherently subject
to risks and uncertainties, and actual results could differ
materially from those currently anticipated due to a number of
factors, which include, but are not limited to, the factors set
forth under the heading "Risk Factors" in the Company's Annual
Report on Form 10-K for the year ended December 31, 2013, updates and additions to those
"Risk Factors" in the Company's interim reports on Form 10-Q, Forms
8-K and in other documents filed by us with the Securities and
Exchange Commission from time to time. Forward-looking statements
may be identified by terms such as "may," "will," "should,"
"could," "expects," "plans," "intends," "anticipates," "believes,"
"estimates," "predicts," "forecasts," "potential," or "continue" or
similar terms or the negative of these terms. Although the Company
believes that the expectations reflected in the forward-looking
statements are reasonable, the Company cannot guarantee future
results, levels of activity, performance or achievements. The
Company has no obligation to update these forward-looking
statements.
For more information, please contact:
Chindex International Inc.
ICR, LLC
William Zima
In U.S.: +1 646-308-1472
In China: +86 (10) 6583-7511
Email: william.zima@icrinc.com
TPG
Brunswick Group Limited
Siobhan Zheng
Email: tpgcoreasia@brunswickgroup.com
Tel: +852 9131-5202
Christina Pantin
Email: tpgcoreasia@brunswickgroup.com
Tel: +852 9166-3697
Shanghai Fosun Pharmaceutical (Group) Co., Ltd
Angel Yi
Email: yijy@fosunpharma.com
Tel: +86 21 23138089
Mobile: +86 13817029841
SOURCE Chindex International, Inc.